Targeting Telomerase and ATRX/DAXX Inducing Tumor Senescence and Apoptosis in the Malignant Glioma

Hueng-Chuen Fan 1,2,3, Chuan-Mu Chen 2,4, Ching-Shiang Chi 1, Jeng-Dau Tsai 5,6, Kuo-Liang Chiang 7,8, Yu-Kang Chang 1,2,3, Shinn-Zong Lin 9,10 and Horng-Jyh Harn 9,11,*

1 Department of Pediatrics, Department of Medical research, Tungs’ Taichung Metroharbor Hospital, Wuchi, Taichung 435, Taiwan; fanhuengchuen@yahoo.com.tw (H.-C.F.); chi-cs@hotmail.com (C.-S.C.); yogurt8306@gmail.com (Y.-K.C.)
2 Department of Life Sciences, National Chung Hsing University, Taichung 402, Taiwan; chchen1@dragon.nchu.edu.tw
3 Department of Rehabilitation, Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli 356, Taiwan
4 The iEGG and Animal Biotechnology Center, and Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung 402, Taiwan
5 School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan; fernand.tsai@msa.hinet.net
6 Department of Pediatrics, Chung Shan Medical University Hospital, Taichung 402, Taiwan
7 Department of Pediatric Neurology, Kuang-Tien General Hospital, Taichung 433, Taiwan; lambier.tw@yahoo.com.tw
8 Department of Nutrition, Hungkuang University, Taichung 433, Taiwan
9 Buddhist Tzu Chi Bioinnovation Center, Tzu Chi Foundation, Hualien 970, Taiwan; shinnzong@yahoo.com.tw
10 Department of Neurosurgery, Buddhist Tzu Chi General Hospital, Hualien 970, Taiwan
11 Department of Pathology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien 970, Taiwan

* Correspondence: arthewduke@gmail.com; Tel.: +886-3-856-1825 (ext. 15615)

Received: 12 December 2018; Accepted: 2 January 2019; Published: 8 January 2019

Abstract: Glioblastoma multiforme (GBM) is a type of brain tumor that is notorious for its aggressiveness and invasiveness, and the complete removal of GBM is still not possible, even with advanced diagnostic strategies and extensive therapeutic plans. Its dismal prognosis and short survival time after diagnosis make it a crucial public health issue. Understanding the molecular mechanisms underlying GBM may inspire novel and effective treatments against this type of cancer. At a molecular level, almost all tumor cells exhibit telomerase activity (TA), which is a major means by which they achieve immortalization. Telomeres can be maintained by telomerase-independent mechanisms related to the mutations of the telomerase reverse transcriptase (TERT) promoter and ATRX/DAXX, which can immortalize and escape senescence and apoptosis. In this article, we review the evidence for triggering GBM cell death by targeting telomerase and the ALT pathway, with an extra focus on a plant-derived compound, butylidene phthalide (BP), which may be a promising novel anticancer compound with good potential for clinical applications.

Keywords: glioblastoma multiforme (GBM); telomerase; alternative lengthening of telomeres; α-thalassemia/mental retardation syndrome X-linked protein (ATRX); death-domain associated protein (DAXX); butylidene phthalide (BP)
1. Introduction

Despite their low incidence rate (25.48 per 100,000 person-years) [1], brain tumors are one of the most frightening diseases, not only because of their high morbidity and mortality rate but also because of the heavy burden they place on patients, their loved ones, and healthcare systems. Glioma, accounting for nearly 80% of all malignant primary tumors of the brain, is classified into astrocytic tumors, including astrocytoma, anaplastic astrocytoma, and glioblastoma multiforme (GBM); oligodendrogliomas; ependymomas, and mixed gliomas, according to their presumed cell of origin [2].

The previous version of the World Health Organization Classification of Tumors of the Central Nervous system (CNS) had classified gliomas into grade I to IV. Grade I gliomas possess low proliferative potential; grades II to IV gliomas are highly invasive and malignant. GBM, a grade IV glioma, is the most aggressive, invasive, and undifferentiated type of tumor. The classification is based on the level of malignancy, which is weighed by the histopathological criteria [3]. However, numerous studies have discovered a significant interobserver variation in the histological diagnosis of gliomas that may affect the typing and grading of glial tumors and subsequently affect the dosages used in radiotherapy and chemotherapy [4]. Since treatment decisions and prognoses are based on histological diagnoses and grading, the latest version of the World Health Organization CNS tumors classification has undergone a complete transformation by incorporating molecular criteria in addition to the pre-existing histological parameters to minimize subjective interpretation of morphological descriptions, as well as interobserver variation, and to provide more objective, quantitative, and reproducible results for recording the grade and lineage of gliomas [5]. GBM, the most malignant type of glioma, accounts for approximately 20% of all brain tumors [6], and total age-adjusted incidence rates of GBM range from 0.59 to 3.69 per 100,000 persons in the world [7]. The incidence rates of GBM in the United States and Taiwan are 3.19 and 0.85 per 100,000 person-years, respectively [8,9]. GBM can occur at any age [10], but is rare in children, and commonly occurs in older patients (mean age = 64 years) [11]. Men have a higher incidence of GBM than women [12]. GBM is notorious for its high mortality rate because only 0.05 to 4.7% of patients survive five years past diagnosis [7]. Current treatment options for GBM include maximal surgical resection, followed by temozolomide and radiation [13]. However, a complete resection is always difficult and postsurgical treatment is usually necessary to prevent recurrence. At the same time, suboptimal penetration through the blood–brain barrier (BBB), drug toxicity, and drug resistance remain major obstacles to the success of chemotherapy [14].

In general, the prognosis of GBM is poor. Even with maximal surgical resection plus radiotherapy with concomitant or subsequent chemotherapy, overall, patients usually have a median survival of approximately 14–15 months from diagnosis [12,15] and the median survival for untreated patients is only three months [16]. The diffuse, invasive nature and location of brain tumors suggest that it is barely possible for an effective treatment to destroy all tumor cells. This reality underscores the need for continuing investigations of novel and alternative therapeutic options, including clinical trials of any agents showing therapeutic potential.

2. Clinical Characteristics of GBM

Patients with brain tumors may present with various signs and symptoms, such as severe, persistent, or recurrent headache; nausea and vomiting; papilledema; seizures; focal neurological and cognitive impairments, such as difficulty in speaking or thinking of words; disturbed vision, hearing, smell, or taste; weakness or paralysis in part of the body; loss of balance; general irritability; drowsiness or a change in personality; flashbacks; and loss of memory [17]. In general, the clinical history of patients with a low-grade astrocytoma may span several years. GBM may present with a short 3–6-month clinical history. Occasionally, the symptoms may develop rapidly, which might be mistaken for a stroke [2]. Moreover, 95% of GBM cases emerge in the supratentorial region, but they can occur in all cortical areas, the brainstem, and the spinal cord [18]. In general, the neuroimaging of GBM is not specific. Some cases may show an irregular lesion with central low-density (Figure 1A) or multiple cystic structures with an enhanced wall on computed tomography (CT) (Figure 1B) or
irregular rim appearance with central necrosis (Figure 1C), or a multi-lobular mass and prominent peritumoral edema with distortive structures of the surrounding brain and ventricles on magnetic resonance imaging (MRI) (Figure 1D–F). The differential diagnoses of the imaging findings are abscess, metastasis, lymphoma, multiple sclerosis, and subacute infarctions [18]. The typical outlook of GBM, which is a single, large, irregular lesion in the white matter, consists of necrosis, cystic and gelatinous areas, and multifocal hemorrhage, causing intermixing of firm and soft textures [19]. Histologically, GBM shows variable cells, from small poorly differentiated cancer cells to large multinucleate cancer cells with multifocal necrosis with pseudopalisading nuclei and high mitotic activity, and proliferative vascular endothelial cells with a glomeruloid structure [19].

Figure 1. GBM. (A) The axial brain CT without contrast shows an irregular mass with central necrosis over the left temporo-parieto-occipital lobes with prominent edematous effect with midline-shifting. (B) The axial brain CT with contrast shows multiple lobulated cystic structures with enhanced wall and septi over the left temporal lobe. (C) The axial brain magnetic brain imaging, T1-weighted repetition time (TR), 450 ms; echo time (TE), 10 s, Achieva 1.5 T, Philips image with gadolinium contrast demonstrated an irregular rim enhanced mass with large central necrosis at the left temporo-parieto-occipital lobes. The prominent edematous effect completely compressed the occipital horn of the left lateral ventricle. (D) The axial brain MRI, T2-weighted (TR, 4980 ms; TE, 100 s) image with gadolinium contrast demonstrated an irregular ovoid mass with necrosis at the left temporo-parieto-occipital lobes. The edematous effect and mass effect were prominent. (E) The axial brain MRI, T1-weighted image with gadolinium contrast demonstrated an irregularly enhanced mass with central necrosis involving the left frontal lobe. The prominent edematous change resulted in brain herniation across the midline. (F) The axial T2-weighted image showed a remarkable perifocal edema in the left frontal lobe, extending to the insula, and corpus callosum genu with subfalcine herniation.
3. Risk Factors

In the past, only a few GBM risk factors were identified as being linked to environmental stimuli, including poor diet, smoking, cellular phones usage or exposure to an electromagnetic field, severe head injury, occupational risk factors and pesticide exposure [19–23]. Steroid hormones were suspected as a possible cause for GBM [24]. Exposure to high-dose radiation is the only confirmed risk factor in extensive retrospective cohort data [23,25]. Allergic conditions, including asthma, hay fever, eczema, and food allergies, may have a protective effect against GBM [26–29], and a meta-analysis study has demonstrated the risk of developing gliomas reduces to 40% in people who have allergies [30], suggesting that immunosurveillance may inhibit the growth of a glioma. Several diseases such as neurofibromatosis type 1 and type 2 [31], tuberous sclerosis (TSC1 and TSC2) [32], Lynch syndrome [33], melanoma-astrocytoma syndrome [34], Ollier disease/Maffucci syndrome [35], and Li-Fraumeni syndrome [36], are associated with the risk of developing gliomas, but only 5–10% of cases of gliomas are reported to show genetic predisposition [21]. The results indicate that the polygenic, instead of the monogenic, model, may explain the incidence pattern of adult gliomas, and results from genome-wide association studies have supported this conclusion by identifying variations in eight genomic regions as contributing to the risk of developing gliomas: telomerase RNA component (TERC), telomerase reverse transcriptase (TERT), epidermal growth factor receptor (EGFR), coiled-coil domain containing 26, cyclin-dependent kinase inhibitor 2B, pleckstrin homology such as domain family B member 1, tumor protein p53 (TP53), and the regulator of telomere elongation helicase 1 (RTEL1) [37–41]. Three of these glioma risk loci (TERC, TERT, and RTEL1) contain genes involved in telomere maintenance. Moreover, recent publications demonstrate that acquired somatic mutations in TERT and α-thalassemia/mental retardation syndrome X-linked protein (ATRX) can affect telomere maintenance in tumor cells and are important in glioma development and prognosis [42–45]. The present review focuses on novel and alternative therapeutic options for treating GBM by inducing tumor senescence and apoptosis through the mechanisms of telomerase and ATRX/death-domain associated protein (DAXX).

4. Etiology and Pathogenesis of GBM

The etiology of GBM is unknown. GBM can be divided into primary and secondary GBMs, based on clinical or histological evidence. Primary GBMs develop rapidly de novo in older patients without clinical or histological evidence of less malignant precursor lesions. Secondary GBM develops more slowly, from low-grade diffuse astrocytoma or anaplastic astrocytoma, in young patients with a significantly better prognosis. Histologically, primary and secondary GBMs are similar, but they differ in their genetic profiles, including the mutations of isocitrate dehydrogenase (IDH), the co-deletion of chromosomes 1p and 19q, mutations of H3F3A, telomerase, TERT, and ATRX.

4.1. Isocitrate Dehydrogenase (IDH)

To elucidate genetic alterations in GBM patients with varying prognoses or responses to specific targeted therapies and to identify subgroups of GBM patients for a better histopathological classification, an integrated genomic analysis was used to identify mutations in isocitrate dehydrogenase 1(IDH1) in 12% of patients with GBM [46]. It was subsequently reported that GBMs without IDH1 mutations often have mutations of isocitrate dehydrogenase 2 (IDH2) [47]. The structures of IDH1 (located on chromosome 2q33.3) and IDH2 (located on chromosome 15q26.1) are homodimeric and share similar sequences and an almost identical protein structure [48]. IDH1 and IDH2 encode two separate, different isocitrate dehydrogenase enzymes, which are nicotinamide adenine dinucleotide phosphate (NADP+) dependent, catalyze oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG), and reduce oxidized nicotinamide adenine dinucleotide (NAD+) or NADP+ to NADH or NADPH. IDH1, localizing in the cytoplasm and peroxisomes, involves cellular metabolism and protection from reactive oxygen species and radiation [49,50]. IDH2, localizing in the mitochondria,
is associated with the regulation of the tricarboxylic acid cycle and protection from oxidative stress [50]. DH1 and IDH2 mutations are mono-allelic, somatic, and missense changes. Mutations in IDH1 commonly affect R132, which is the binding site for isocitrate [46]. Mutations in IDH2 only affect R172 and R140 [47,51]. Mutant IDH possesses catalytic activity to convert α-KG to 2-hydroxyglutarate (2-HG) [52]. Excessive 2-HG is a metabolic hallmark of certain subtypes of gliomas [53]. Both mutated IDH1 and IDH2 are common in adult gliomas (WHO grades II and III) and secondary GBM (WHO grade IV). Mutated IDH1 and IDH2 are very rare in childhood GBM [54], suggesting gliomas with mutated IDH are clinically and genetically different from those with wild-type (WT) IDH genes.

4.2. Co-Deletion at Chromosome Regions 1p/19q

The complete deletion of chromosomes 1p and 19q is common in oligodendrogliomas and occur in 50–70% of both low-grade and anaplastic tumors [55–58]. These findings suggest that chromosomes 1p and 19q may contain tumor suppressor genes, including the far upstream element binding protein 1 (FUBP1) on chromosome 1p and the capicua transcriptional repressor (CIC) on chromosome 19q [59–61]. The FUBP1 expresses a single-stranded DNA-binding protein that can bind to several DNA regions, which harbor the far upstream element (FUSE) that is localized in the upstream of c-Myc. One function of FUSE is to regulate c-Myc in undifferentiated cells [62]. CIC, a tissue-specific transcriptional repressor, is expressed in the developing CNS and its dysfunction is associated with spinocerebellar ataxia type 1. This CIC-DNA interaction can be inhibited through the activation of the receptor tyrosine kinase (RTK) core signaling molecule mitogen-activated protein kinase (MAPK), which then allows for the transcription of CIC targets through this RTK-MAPK signaling axis. CIC alterations are common in specific cancer types (e.g., oligodendroglioma and Ewing-like sarcomas) [63]. Two clinical trials have clarified associations between combined 1p/19q co-deletion and an improved chemotherapeutic response and prognosis in oligodendrogliomas [64,65]. However, partial 1p or 19q deletion is more common in astrocytic tumors and secondary GBM but rare in primary GBM [66–68].

4.3. Mutations of H3F3A

Inside the nucleus, DNA, RNA and proteins form chromatin, which packs the DNA to a smaller volume and prevents the long DNA strands from being tangled. The structure of the chromatin is like “beads on a string”. The nucleosome is the “bead”, which is a basic unit of chromatin. Histones, nuclear proteins, can store DNA, modulate chromatin structure, impact gene expression, and regulate almost all DNA metabolic processes through post-translational modification, which includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation [69]. Each nucleosome is composed of a histone octamer, which is composed of two copies each of the core histone H2A, H2B, H3, and H4. H1, which does not contribute to the nucleosome bead, binds to the linker DNA region between nucleosomes, helping pack the chromatin into higher order structures. A chain of nucleosomes is compacted to form a chromosome [70]. Histone H3s, which have several variants, include H3.1, H3.2, and H3.3. H3.1 is encoded by HIST1H3A-J. H3.2 is encoded by HIST2H3A, HIST2H3C, and HIST2H3D. H3.3 is encoded by H3F3A and H3F3B [71]. Numerous H3 lysine residues can be post-translationally modified, including acetylated at lysines 9, 14, 18, 23, and 56; methylated at arginine 2 and lysines 4, 9, 27, 36, and 79, and phosphorylated at ser10, ser28, Thr3, and Thr11 [72]. Mutation of H3F3A, including K27M substitution, in which a lysine residue on the histone H3 tail is substituted for a methionine, were discovered in diffused intrinsic pontine glioma (DIPG) [73]. As the location of the H3F3A at lysine 27 is at or near critical regulatory histone residues, therefore, the alternations of mutant K27M on genes, which should be silent, produce widespread aberrant DNA methylation and deregulation of gene expression, impede physiological differentiation and to drive cell transformation [74]. Furthermore, in the WHO CNS tumor classification 2016, the principle of an integrated diagnosis was introduced with the combination of histological and molecular features, exemplified in the novel entity “diffuse midline glioma, H3K27M- mutant” [5]. The mutation in HIST1H3B-C, have been detected in approximately 10% of DIPG [75]. Another mutation of H3F3A,
encoding a glycine 34 to arginine or valine (G34R/V) substitution, is reported in a smaller portion of pediatric and young adult high-grade astrocytoma [54]. H3F3G34 mutations may drive pediatric GBM through mismatch repair (MMR) deficiency [76] and upregulation of v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian) (MYCN) [77].

4.4. Telomeres and Telomerase

A telomere is a capping structure located at the end of a linear chromosome. As most prokaryotes have circular chromosomes, they do not have telomeres; on the other hand, telomeres in vertebrates consist of a region of repeats of the six-nucleotide sequence TTAGGG at the ends of chromosomes, which themselves carry the complementary DNA strand sequence, AATCCC. In humans, the TTAGGG sequence repeats in tandem approximately 3000–20,000 times [78,79]. The sequence is bound by the shelterin complex, which is formed by TRF1, TRF2, TPP1, TIN2, POT1 and RAP1 [80]. Telomeres are known to maintain the stability of chromosomes and protect genes [81,82]. Chromosomes without this capping structure, meanwhile, become truncated and fuse with neighboring chromosomes [83].

In the process of chromosome replication, the synthesis of Okazaki fragments requires that RNA primers attach to the lagging strand. The shedding RNA then causes telomere shortening. As such, the accumulative loss of telomeres can eventually cause cell cycle arrest and apoptosis, leading to speculation that the progressive reduction in telomere length may play a key role in determining the timing of in vitro cellular senescence [84,85]. Therefore, telomeres are also viewed by some as a sort of biological clock that controls normal cell proliferation [86]. It is estimated that the human telomere loses approximately 24.8 to 27.7 base pairs per year [87,88]. There are several factors, however, that affect the rate of telomere shortening, including the host’s age [89]; gender [90]; genetic and epigenetic regulation [91–93]; social and economic background [94,95], and life style factors, such as the lack or presence of exercise, obesity, smoking, and unhealthy diets [88,95,96] (Figure 2). Individuals with shorter telomeres are known to be associated with various age-related diseases and conditions, such as heart failure [97], coronary heart disease [98–100], diabetes [101], osteoporosis [102], and a shorter lifespan [103–105]. Although the shorter length of telomeres is generally thought to be a marker of poor health and aging, it can lead to genomic instability [106–108] and elevated telomerase activity (TA) [109,110], resulting in a potential cancer predisposition factor.

Cell division leads to progressive telomere shortening, resulting in cell senescence; however, the shortening of telomeres can be counteracted by telomerase [111]. Telomerase, an RNA-dependent DNA polymerase, is expressed in developing embryos, in reproductive cells (i.e., proliferating germlines), in activated immune cells, and transiently, in adult stem cells, but telomerase is turned off in most adult human tissues. In immortalized cells, telomere length remains stable, with the activation of telomerase being considered one of the main mechanisms underlying this stability [111–113]. TA is exhibited in almost all human tumors and in tumor-derived cell lines, while most human somatic cells do not display TA, except for highly proliferative cells, such as bone marrow cells [114,115]. Telomerase, which is made up of TERT, TERC, and specialized proteins (e.g., dyskerin), preserves telomere stability by adding TTAGGG repeats to the end of the given chromosome (capping) in rapidly dividing cells [112,113,116], using its complementary TERC sequence as the template [117], together with TERT subunit as the catalytic component [111]. Activities of TERT are frequently up-regulated in human cancers, which is thought to be a critical mechanism contributing to human tumorigenesis [118,119]. Studies have identified two cancer-specific TERT promoter mutations (C228T and C250T) [44] in the activation of telomerase in various cancer cells [120,121], including GBM [122]. The two mutations in the TERT, which cause TERT activation to increase TA to elongate telomere length [44,123], lead to the proliferative, anti-senescence, and immortal properties of tumor cells. Mutations in the TERT promoter have been detected in more than 50% of primary adult GBM, and these mutations are correlated with EGFR, IDH1, IDH2, TP53, and ATX mutations and increased TA [45,123–126]. Mutations in the TERT promoter have been detected in 3–7% of pediatric GBM [44,123] and tumor cells in this group maintain or increase telomere length through alternative lengthening of telomeres (ALT) pathway [127,128].
shortening DNA leading to senescence and/or apoptosis, or cancer development. Arrow: factors affecting telomeres shortening.

### 4.5. Alternative Lengthening of Telomeres, α-Thalassemia X-Linked Intellectual Disability, and Death-Domain-Associated Protein

TA was detected in 76% of cervical cancer cases [129], 54% of medullary thyroid cancer cases [130], 42% of well-differentiated papillary thyroid cancer cases [131], 86.6% of non-small cell lung cancer cases [132], and > 80% of hepatocellular carcinoma cases [133]. Although telomerase reactivation is the most common mechanism of telomeric repeat addition in cancers [109], there is a convincing argument that TA is not the only way for tumors to become immortalized; otherwise, these tumors would have shrunk and died unless they managed to boost their TA to maintain their telomere length. Additionally, Indeed, 5–10% cancer cases exploit a telomerase-independent mechanism to elongate their telomeres, a phenomenon that is also known as ALT [134]. In addition to immortalized cells and cancer cells, ALT exists in non-neoplastic tissues, in endothelial, stromal, and some epithelial cells [135]. Although the prevalence of the ALT phenotype in cancers is low, ALT is common in certain cancer subtypes, including gliomas [136]. While primary GBM has been found to employ telomerase activation, nearly 75% of WHO grades II–III astrocytomas and secondary GBMs, with normal telomerase expression and WT TERT promoter, was observed to employ ALT for the maintenance of telomere length and genome stability [60,137]. The transformation from telomerase-dependent to ALT-mediated telomere lengthening is considered one of the strategies cancer cells adopt to escape cell senescence and apoptosis caused by telomerase dysfunction or absence [138,139]. ALT, which is not present in normal cells, often begins with a loss of chromatin remodeling proteins in the telomeres, with a resulting DNA damage response, recombination, and abnormal protein behavior that initiates ALT [140].

α-thalassemia X-linked intellectual disability (ATRX) syndrome is characterized by distinctive craniofacial features, genital anomalies, severe developmental delays, hypotonia, intellectual disability, and mild-to-moderate anemia secondary to α-thalassemia [141]. The ATRX gene, which encodes a SWItch (SWI)/sucrose non-fermenting(SNF)-like chromatin remodeling protein, is frequently mutated in a variety of tumors, including adult lower-grade gliomas, pediatric GBM pediatric adrenocortical carcinoma, osteosarcoma, and neuroblastoma [142]. Cancer cells with a loss of ATRX gene display large and bright telomeric DNA foci that are significantly correlated with ALT [127], suggesting that ATRX may be a suppressor of the ALT mechanism and a good prognostic factor in cancers, such as in GBMs [143]. Moreover, the forced expression of ATRX in ALT-positive and
ATRX-negative cell lines abolishes ALT-associated phenotypes [144,145], but ATRX, either by knocking out or knocking down in telomerase-positive cell lines did not present similar findings [138,145–148], suggesting that an ATRX loss alone is not sufficient for ALT activation. DAXX was originally identified as a Fas death receptor binding protein that induced apoptosis via JNK pathway activation. Thus, it was coined the death-domain-associated protein, DAXX [149]. ATRX and DAXX were initially seemed to be irrelevant. Analyzing H3.3 chaperone complexes identified ATRX and DAXX [150–152]. ATRX, in collaboration with DAXX, deposits H3.3 into telomeric and pericentromeric chromatin to prevent the formation of G-quadruplex DNA (G-4 DNA), a type of DNA structure that promotes homologous recombination repair and DNA-repair mechanisms, leading to telomere shortening [127,144,153]. These results reinforce the value of the ATRX/DAXX/H3.3 complex in ALT suppression (Figure 3). Gliomas with a WT TERT promoter frequently harbor mutations of ATRX to activate ALT [44]. Yang et al. successfully switched the telomere lengthening machinery of telomerase-positive cancer cells (HTC75) to an ALT-mediated telomere elongation mechanism by knocking out the TERT, inducing telomeric DNA damage, and disrupting the ATRX/DAXX complex [154], suggesting that ATRX and TERT mutations are mutually exclusive in conferring a selective growth advantage in cancers through telomere maintenance. Therefore, effective treatments should not only target TA in cancer cells but should also be aimed at modulating the proper function of the ATRX/DAXX/H3.3 complex to destroy tumor cells.

Figure 3. Telomeres are cap-like features at the ends of chromosomes that help protect them when cells divide. Telomeres contain thousands of repeats of the six-nucleotide sequence TTAGGG at the chromosome ends, with complementary DNA strand sequences AATCCC. 1. In the process of cell division, chromosome replication causes progressive telomere shortening, resulting in cell cycle arrest and apoptosis, leading to cellular senescence. 2. The shortening of telomeres can be counteracted by telomerase, which is made up of TERT, TERC, and specialized proteins. Telomerase maintains the length of telomeres stability by adding TTAGGG repeats to the end of the given chromosome, using its complementary TERC sequence as the template, together with TERT subunit as the catalytic component. 3. ALT is a phenomenon that 5–10% cancer cases exploit a telomerase-independent mechanism to elongate their telomeres [134]. The transformation from telomerase-dependent to ALT-mediated telomere lengthening may be one of strategies cancer cells adopt to escape cell senescence and apoptosis caused by telomerase dysfunction or absence [138,139]. ATRX, in collaboration with DAXX and H3.3 promotes the processes of telomere shortening [127,144,153]. Evidence shows the ATRX/DAXX/H3.3 complex in ALT suppression and a good prognostic factor in GBMs [143]. Arrow: possible pathway. T-bar: inhibition.
5. Novel and Alternative Therapeutic Options for Treating GBM

There are several promising novel anticancer compounds with good potential for clinical applications. For example, the inhibition of mutant IDH may potentially have anticancer effects. Accordingly, the Food and Drug Administration (FDA) has approved the mutant IDH1 inhibitor, ivosidenib [155], and IDH2 inhibitor, enasidenib [156] for adults with relapsed or refractory acute myeloid leukemia, inhibitors of mutant IDH have entered clinical trials for glioma treatment [157,158]. Two compounds, precatorine and abrine, are reported to have promising effects against tumors with mutant IDH2/R140 [159]. Multiple approaches have been used to target telomerase through the development of vaccines, antisense oligonucleotides, and small-molecule inhibitors targeting TERT or TERC, such as BIBR1532, a small-molecule telomerase inhibitor, which disturbs the DNA substrate elongation upon template copying by reducing the number of TTAGGG repeats [160]; GRN163L, a direct telomerase RNA template antagonist binding with high specificity and affinity at the active site of TERT, causing a complete inhibition of the telomerase [161]; GV1001, an MHC II-peptide derived from the TERT vaccine with anti-inflammatory, anti-apoptotic, and antioxidant properties [162]; GRNVAC1, an autologous dendritic cell vaccine, consisting of RNA for the protein component of TERT and a portion of a lysosomal targeting signal, which guides the TERT to a lysosome enhancing its function to degrade into small peptides and leading to a stronger polyclonal immune response specific to all TERT epitopes expressed by patient tumors [163]; Vx-001, a TERT-derived peptide composed of a native cryptic peptide (TERT572) and an optimized variant (TERT572Y), showing significant inhibition of various types of tumor growth [164]; BRACO19, a promising small-molecule G-4 DNA stabilizing ligand, causing the shortening of telomeres [165]; geldanamycin, an HSP90 inhibitor, blocking the ATP-dependent binding of HSP90 to p23, causing disruption of the chaperone assembly leading to inhibition of the telomerase [166]; curcumin, a natural compound, causing time- and dose-dependent inhibition of the nuclear localization of TERT [167]; telomestatin, a natural product composed of a large array of polyoxazole rings that form macrocyclic linkages (R-telomestatin), leading to telomere shortening and apoptosis by activation of p38 MAPK, caspase-3, and poly-(ADP-ribose) polymerase [168]; and telomelysin, an oncolytic adenovirus with a modified gene containing a TERT promoter, showing promising antitumor activity through apoptotic and non-apoptotic pathways [169]. Although imetelstat, an oligonucleotide inhibitor, blocking the template region of telomerase [170], has been shown to inhibit TA and cancer cell proliferation in vitro and in animal [163] and in phase 1 studies [161], the regimen has proved too toxic in children with recurrent CNS tumors [171]. INO-5401, a combination of three DNA plasmids targeting the Wilms tumor gene-1 (WT1) antigen, the prostate-specific membrane antigen, and TERT genes, is being administered intramuscularly followed by electroporation in combination with cemiplimab, chemoradiation, and radiation to newly diagnosed GBM patients (NCT03491683). Meanwhile, eribulinmesylate, an FDA-approved drug for breast cancer and liposarcoma, has been shown to effectively and specifically inhibit the RNA-dependent RNA polymerase activity of TERT in multiple human GBM cell lines in preclinical mouse brain tumor models. Intraperitoneally administered erbulin also significantly prolongs the survival of mouse GBM models. Following these positive preclinical results, a phase 2 clinical trial is currently underway to investigate the use of eribulinmesylate in patients with recurrent GBM following the failure of treatment with temozolomide and bevacizumab [172].

Currently, the investigated agents targeting telomerase for cancer treatments are considered ineffective in ALT-dependent cancers or cancers adapting ALT mechanisms. Hence, to achieve effective tumor cell senescence and apoptosis by blocking telomere lengthening, not only should the telomerase-associated pathway be targeted, but the proper functioning of the ATRX/DAXX/H3.3 complex should be retained. Given the fast-paced development of genome editing technology, gene therapies targeting ATRX are considered to be among the potential treatments for ALT-positive cancers [154]. Additionally, as the association of H3F3A mutation with loss of ATRX and ALTis reported [128], and mutations in ATRX are found to cause changes in the patterns of DNA methylation of several highly repeated sequences [173], and DNA methylation patterns are tightly
connected to histone 3 lysine K27 trimethylation (H3K27me3) patterns, and loss of H3K4me3 and retention of H3K4me2 or H3K27me3 are correlated with an increase in DNA methylation [54], these findings suggest that epigenic therapeutics targeting GBM by histone deacetylase (HDAC) inhibitors, including AR-42 [174], panobinostat [175], cyclic benzamides, hydroxamate derivates and Diallyl-trisulfides [176], and H3-K27M inhibitor, GSK-J4 [177] may be effective. Although several modern strategies to fight GBM through modulating telomerase or ALT are promising, there is still a long way to go to develop a complete cure for GBM. Natural products have a long history of wide use as cancer treatments in China. Traditional Chinese medicines typically make use of plants or their derivatives and are usually considered alternative therapeutic options or palliative treatments, especially in the context of cancer treatment. However, there is an increasing amount of evidence supporting the use of plant extracts in direct and primary cancer treatments. For example, Angelica sinensis (Oliv.) Diels (AS), commonly known as dong quai, is used for the treatment of gastric mucosal damage, hepatic injury, chronic glomerulonephritis, impaired myocardial blood flow, and menopause in traditional Chinese medicine [178], and has been shown to have promising effects against brain cancers and other types of cancer [179–183]. The chloroform extract of AS, butylidenephthalide (BP), inhibits the proliferation of human GBM through the down-regulation of TERT and the consequent reduction in TA, leading to tumor senescence [184]. Meanwhile, BP has been found to show strong anti-proliferative effects against GBM in vitro and in vivo through inducing cell growth arrest and apoptosis [185]. In research involving two kinds of brain cancer cell lines, DBTRG-05MG and GBM 8401, BP was found to reduce TERT mRNA and protein expression in a dose-dependent manner, which is associated with the reduction of TA but independent of c-Myc regulation. By repressing TERT transcriotional activity, BP inhibits TA, an effect that is followed by human brain tumor cell senescence, such that the cells stay viable but stop synthesizing DNA and instead generate senescence-associated β-galactosidase [184]. In DBTRG-05MG tumor cells, BP promotes the phosphorylation of p53 and increases p53 expression; another two senescence-associated markers, p21 and p16, also increase after BP treatment. The BP-induced cell cycle arrest is associated with up-regulated cyclin-dependent kinase inhibitors (e.g., p21), which in turn, decreases the phosphorylation of retinoblasma proteins. Moreover, in BP-treated GBM cells, the level of apoptosis-associated proteins, such as caspase 8, procaspase 9, and procaspase 3, dramatically increases, and these proteins stay activated. Both p53-dependent and p53-independent pathways are shown to be involved in BP-induced apoptosis. In vivo, BP induces the shrinkage of in situ GBM and significantly prolongs survival [182]. Brain tumors are especially difficult to treat due to the BBB, which, by its nature, prevents toxins, large molecules, and xenobiotics in circulation from entering the brain. To overcome this barrier, the group involved in this study developed biodegradable polyanhydride wafers, which were tested by implanting them into xenograft animal models together with human GBM cells. The system served as an intracranial drug delivery instrument that enabled sufficient BP to reach the tumor site without causing significant harm to the surrounding normal brain tissue. The group found that the BP wafers dose-dependently reduced the size of brain tumors without relevant adverse effects in the animals. One of the critical mechanisms of these BP-wafers was the reduction in TERT mRNA expression, which leads to tumor senescence [186]. In sum, several studies reviewed herein demonstrate the substantial effects of BP against GBM, which supports further clinical investigations of the compound.

6. Conclusions

GBM can grow in all cortical areas, the brainstem, and the spinal cord. Patients with GBM may rapidly present with various signs and symptoms. It is so aggressive and invasive that even with maximal surgical resection plus radiotherapy with concomitant or subsequent chemotherapy, GBM remains an incurable tumor and a median survival of less than 2 years from diagnosis [12,15]. This review summarizes examples of current advances in the molecular mechanisms underlying GBM, such as mutant IDH, co-deletion at chromosome regions 1p/19q, mutations of H3F3A,
telomerase, and ALT, and explores the potential of several novel and alternative therapeutic options, including various mutant IDH inhibitors [157,158]; telomerase vaccines, antisense oligonucleotides, peptide and small-molecule inhibitors targeting telomerase and TERT-targeting therapies [160–169]; gene therapies targeting ATRX [154]; epigenetic therapeutics, such as histone deacetylase (HDAC) inhibitors [174–176] and methylation inhibitors [177]. In addition, plant-derived compounds, for example, BP, the chloroform extract of AS, has been found to inhibit the proliferation of GBM through the down-regulation of TERT and the consequent reduction in TA, leading to tumor apoptosis and senescence in vitro and in vivo [184,185]. However, GBM may use either one, or some, or all these mechanisms or another to cause excessive growth and progression, therefore, single-agent therapies may have no or low significant benefits. Moreover, because the crosstalk in signaling networks of these targets may affect the efficacy of the novel agents, effective treatments should not only target TA in cancer cells but should also be aimed at modulating the proper function of the ATRX/DAXX/H3.3 complex to destroy tumor cells. These therapies work in conjunction with the current standard of care, it is likely that patient survival and quality of life will be greatly improved with several modern strategies to fight GBM through modulating telomerase, epigenetics, or ALT. Of course, a wide range of additional investigations will be required to follow up on the promising leads generated by the studies reviewed herein, but taken together, these studies suggest various pathways to the more effective treatment of GBM and other gliomas in the future.

**Author Contributions:** H.-C.F. conducted the manuscript writing; C.-M.C. revised the manuscript critically for important intellectual content and provided crucial opinions regarding figures; C.-S.C. provided clinical data and critical questions and suggestions to the manuscripts; J.-D.T. summarized several references and provided opinions regarding the GBM; K.-L.C. provided ATRX and DAXX papers and pointed out several problems in this paper and revised them; Y.-K.C. provided useful suggestions and comments regarding the risk factors; S.-Z.L. provided critical questions and suggestions to the GBM treatment and molecular mechanisms and several clinical experience; H.-J.H. conceptualized the review, supervised all aspects of the study, critically reviewed and revised the manuscript, and most important, provided the background knowledge of BP and present and future use of the chemical for patients with GBM. All authors read and approved the final manuscript.

**Funding:** This work was supported by grants from the Tungs’ MetroHarbor Hospital (TTMHH-108R00002 and TTMHH-107R0006), This study was funded by Buddhist Tzu Chi Bioinnovation Center, Tzu Chi Foundation, Hualien, Taiwan; and Ministry of Science and Technology, Taiwan (MOST 106-2320-B-303-001-MY3 and MOST 106-2320-B-303-002-MY3); and the Higher Education Sprout Project by the Ministry of Education (MOE-107-S-0023-A) in Taiwan. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. de Robles, P.; Fiest, K.M.; Frolkis, A.D.; Pringsheim, T.; Atta, C.; St Germaine-Smith, C.; Day, L.; Lam, D.; Jette, N. The worldwide incidence and prevalence of primary brain tumors: A systematic review and meta-analysis. *Neuro Oncol.* 2015, 17, 776–783. [CrossRef] [PubMed]
2. Hanif, F.; Muzaffar, K.; Perveen, K.; Malhi, S.M.; Simjee Sh, U. Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment. *Asian Pac. J. Cancer Prev.* 2017, 18, 3–9. [PubMed]
3. Louis, D.N.; Ohgaki, H.; Wiestler, O.D.; Cavenee, W.K.; Burger, P.C.; Jouvet, A.; Scheithauer, B.W.; Kleihues, P. The 2007 WHO classification of tumours of the central nervous system. *Acta Neuropathol.* 2007, 114, 97–109. [CrossRef] [PubMed]
4. van den Bent, M.J. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: A clinician’s perspective. *Acta Neuropathol.* 2010, 120, 297–304. [CrossRef]
5. Louis, D.N.; Perry, A.; Reifenberger, G.; von Deimling, A.; Figarella-Branger, D.; Cavenee, W.K.; Ohgaki, H.; Wiestler, O.D.; Kleihues, P.; Ellison, D.W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. *Acta Neuropathol.* 2016, 131, 803–820. [CrossRef] [PubMed]
6. CBTRUS. Central Brain Tumor Registry of the United States CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004–2008; CBTRUS Central Brain Tumor Registry of the United States: Hinsdale, IL, USA, 2014.

7. Ostrom, Q.T.; Bauchet, L.; Davis, F.G.; Deltour, I.; Fisher, J.L.; Langer, C.E.; Pekmezci, M.; Schwartzbaum, J.A.; Turner, M.C.; Walsh, K.M.; et al. The epidemiology of glioma in adults: A “state of the science” review. *Neuro Oncol.* 2014, 16, 896–913. [CrossRef] [PubMed]

8. Chien, L.N.; Gittleman, H.; Ostrom, Q.T.; Hung, K.S.; Sloan, A.E.; Hsieh, Y.C.; Kruchko, C.; Rogers, L.R.; Wang, Y.F.; Chiou, H.Y.; et al. Comparative Brain and Central Nervous System Tumor Incidence and Survival between the United States and Taiwan Based on Population-Based Registry. *Front. Public Health* 2016, 4, 151. [CrossRef]

9. Dolecek, T.A.; Propp, J.M.; Stroup, N.E.; Kruchko, C. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. *Neuro Oncol.* 2012, 14 (Suppl. 5), v1–v49. [CrossRef]

10. Rock, K.; McArdle, O.; Forde, P.; Dunne, M.; Fitzpatrick, D.; O’Neill, B.; Faul, C. A clinical review of treatment outcomes in glioblastoma multiforme—The validation in a non-trial population of the results of a randomised Phase III clinical trial: Has a more radical approach improved survival? *Br. J. Radiol.* 2012, 85, e729–e733. [CrossRef]

11. Tamimi, A.F.; Juweid, M. Epidemiology and Outcome of Glioblastoma. In *Glioblastoma*; De Vleeschouwer, S., Ed.; Codon Publications: Brisbane, Australia, 2017.

12. Thakkar, J.P.; Dolecek, T.A.; Horbinski, C.; Ostrom, Q.T.; Lightner, D.D.; Barnholtz-Sloan, J.S.; Villano, J.L. Epidemiologic and molecular prognostic review of glioblastoma. *Cancer Epidemiol. Biomarkers Prev.* 2014, 23, 1985–1996. [CrossRef] [PubMed]

13. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N. Engl. J. Med.* 2005, 352, 987–996. [CrossRef]

14. Fan, H.C.; Chi, C.S.; Chang, Y.K.; Tung, M.C.; Lin, S.Z.; Harn, H.J. The Molecular Mechanisms of Plant-Derived Compounds Targeting Brain Cancer. *Int. J. Mol. Sci.* 2018, 19, 395. [CrossRef] [PubMed]

15. Ohka, F.; Natsume, A.; Wakabayashi, T. Current trends in targeted therapies for glioblastoma multiforme. *Neurol. Res. Int.* 2012, 2012, 878425. [CrossRef] [PubMed]

16. Malmstrom, A.; Gronberg, B.H.; Marosi, C.; Stupp, R.; Frappaz, D.; Schultz, H.; Abacioglu, U.; Tavelin, B.; Lhermitte, B.; Hegi, M.E.; et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial. *Lancet Oncol.* 2012, 13, 916–926. [CrossRef]

17. Available online: https://brainfoundation.org.au/medical-information/c4-brain-tumour/diagnosis-of-brain-tumour (accessed on 12 December 2018).

18. Nakada, M.; Kita, D.; Watanabe, T.; Hayashi, Y.; Teng, L.; Pyko, I.V.; Hamada, J. Aberrant signaling pathways in glioma. *Cancers* 2011, 3, 3242–3278. [CrossRef] [PubMed]

19. Agnihotri, S.; Burrell, K.E.; Wolf, A.; Jalali, S.; Hawkins, C.; Rutka, J.T.; Zadeh, G. Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. *Arch. Immunol. Ther. Exp. (Warsz)* 2013, 61, 25–41. [CrossRef]

20. Adamson, C.; Kanu, O.O.; Mehta, A.I.; Di, C.; Lin, N.; Mattox, A.K.; Bigner, D.D. Glioblastoma multiforme: A review of where we have been and where we are going. *Expert Opin. Investig. Drugs* 2009, 18, 1061–1083. [CrossRef]

21. Fisher, J.L.; Schwartzbaum, J.A.; Wrensch, M.; Wiemels, J.L. Epidemiology of brain tumors. *Neurol. Clin.* 2007, 25, 867–890. [CrossRef]

22. Inskip, P.D.; Tarone, R.E.; Hatch, E.E.; Wilcosky, T.C.; Shapiro, W.R.; Selker, R.G.; Fine, H.A.; Black, P.M.; Loeffler, J.S.; Linet, M.S. Cellular-telephone use and brain tumors. *N. Engl. J. Med.* 2001, 344, 79–86. [CrossRef]

23. Ohgaki, H. Epidemiology of brain tumors. *Methods Mol. Biol.* 2009, 472, 323–342. [CrossRef]

24. Kabat, G.C.; Etgen, A.M.; Rohan, T.E. Do steroid hormones play a role in the etiology of glioma? *Cancer Epidemiol. Biomarkers Prev.* 2010, 19, 2421–2427. [CrossRef] [PubMed]

25. Bondy, M.L.; Scheurer, M.E.; Malmer, B.; Barnholtz-Sloan, J.S.; Davis, F.G.; Il’yasova, D.; Kruchko, C.; McCarthy, B.J.; Rajaraman, P.; Schwartzbaum, J.A.; et al. Brain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium. *Cancer* 2008, 113 (Suppl. 7), 1953–1968. [CrossRef] [PubMed]
26. Berg-Beckhoff, G.; Schuz, J.; Blettner, M.; Munster, E.; Schlaefke, K.; Wahren, J.; Schlehofer, B. History of allergic disease and epilepsy and risk of glioma and meningioma (INTERPHONE study group, Germany). Eur. J. Epidemiol. 2009, 24, 433–440. [CrossRef] [PubMed]

27. Il'yasova, D.; McCarthy, B.; Marcello, J.; Schildkraut, J.M.; Moorman, P.G.; Krishnamachari, B.; Ali-Osman, F.; Bigner, D.D.; Davis, F. Association between glioma and history of allergies, asthma, and eczema: A case-control study with three groups of controls. Cancer Epidemiol. Biomarkers Prev. 2009, 18, 1232–1238. [CrossRef]

28. McCarthy, B.J.; Rankin, K.; Il'yasova, D.; Erdal, S.; Vick, N.; Ali-Osman, F.; Bigner, D.D.; Davis, F. Assessment of type of allergy and antihistamine use in the development of glioma. Cancer Epidemiol. Biomarkers Prev. 2011, 20, 370–378. [CrossRef]

29. Turner, M.C.; Krewski, D.; Armstrong, B.K.; Chretin, A.; Giles, G.G.; Hours, M.; McBride, M.L.; Parent, M.E.; Sadetzki, S.; Siemiatycki, J.; et al. Allergy and brain tumors in the INTERPHONE study: Pooled results from Australia, Canada, France, Israel, and New Zealand. Cancer Causes Control 2013, 24, 949–960. [CrossRef]

30. Linos, E.; Raine, T.; Alonso, A.; Michaud, D. Atopy and risk of brain tumors: A meta-analysis. J. Natl. Cancer Inst. 2007, 99, 1544–1550. [CrossRef]

31. Mulvihill, J.J.; Parry, D.M.; Sherman, J.L.; Pikus, A.; Kaiser-Kupfer, M.I.; Eldridge, R. NIH conference. Cancer Epidemiol. Biomarkers Prev. Australia, Canada, France, Israel, and New Zealand. Cancer Causes Control 2013, 24, 949–960. [CrossRef]

32. Cristofori, E.; Colvecchio, A.; Riscaldani, R.; Micoli, G. Bilateral renal angiomyoliposarcoma and glioblastoma multiforme in tuberous sclerosis. Folia Hered. Pathol. (Milano) 1968, 17, 79–83.

33. Therkildsen, C.; Ladelund, S.; Rambøe, E.; Persson, A.; Petersen, A.; Nilbert, M. Glioblastomas, astrocytomas and oligodendroglomas linked to Lynch syndrome. Eur. J. Neurol. 2015, 22, 717–724. [CrossRef]

34. Bahuau, M.; Vidaud, D.; Schildkraut, J.M.; Moorman, P.G.; Krishnamachari, B.; Ali-Osman, F.; Bigner, D.D.; Davis, F. Association between glioma and history of allergies, asthma, and eczema: A case-control study with three groups of controls. Cancer Epidemiol. Biomarkers Prev. 2009, 18, 1232–1238. [CrossRef]

35. Mellon, C.D.; Carter, J.E.; Owen, D.B. Ollier’s disease and Maffucci’s syndrome: Distinct entities or a continuum.

36. Lynch, H.T.; McComb, R.D.; Osborn, N.K.; Wolpert, P.A.; Lynch, J.F.; Wszolek, Z.K.; Sidransky, D.; Steg, R.E. Lynch syndrome and oligodendroglias linked to Lynch syndrome. Eur. J. Neurol. 2015, 22, 717–724. [CrossRef]

37. Sanson, M.; Hosking, F.J.; Shete, S.; Zeleniak, D.; Dobbins, S.; Ma, Y.; Enciso-Mora, V.; Idibaih, A.; Delattre, J.Y.; Hoang-Xuan, K.; et al. Chromosome 7p11.2 (EGFR) variation influences glioma risk. Hum. Mol. Genet. 2011, 20, 2897–2904. [CrossRef] [PubMed]

38. Shete, S.; Hosking, F.J.; Robertson, L.B.; Dobbins, S.E.; Sanson, M.; Malmer, B.; Simon, M.; Marie, Y.; Boisselier, B.; Delattre, J.Y.; et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat. Genet. 2011, 43, 899–904. [CrossRef] [PubMed]

39. Stacey, S.N.; Sulem, P.; Jonasdotttt, A.; Masson, G.; Gudmundsdotttt, J.; Gudbjartsson, D.F.; Magnussson, O.T.; Gudjonssonn, S.A.; Sigurgeirsson, H.; Thorisdotttt, K.; et al. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat. Genet. 2011, 43, 1098–1103. [CrossRef]

40. Walsh, K.M.; Codd, V.; Smirnov, I.V.; Rice, T.; Decker, P.A.; Hansen, H.M.; Kollmeyer, T.; Kose, M.L.; Molinaro, A.M.; McCoy, L.S.; et al. Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nat. Genet. 2011, 43, 1098–1103. [CrossRef]

41. Wrensch, M.; Jenkins, R.B.; Chang, J.S.; Yeh, R.F.; Xiao, Y.; Decker, P.A.; Ballman, K.V.; Berger, M.; Buckner, J.C.; Chang, S.; et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat. Genet. 2009, 41, 905–908. [CrossRef]

42. Eckel-Passow, J.E.; Lachance, D.H.; Molinaro, A.M.; Walsh, K.M.; Decker, P.A.; Sicotte, H.; Pekmezci, M.; Rice, T.; Kose, M.L.; Smirnov, I.V.; et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N. Engl. J. Med. 2015, 372, 2499–2508. [CrossRef]

43. Kannan, K.; Inagaki, A.; Silber, J.; Gorovets, D.; Zhang, J.; Kastenhuber, E.R.; Heguy, A.; Petrini, J.H.; Chan, T.A.; Huse, J.T. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget 2012, 3, 1194–1203. [CrossRef]
44. Killela, P.J.; Reitman, Z.J.; Jiao, Y.; Bettegowda, C.; Agrawal, N.; Diaz, L.A.; Jr Friedman, A.H.; Friedman, H.; Gallia, G.L.; Giovanella, B.C.; et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. *Proc. Natl. Acad. Sci. USA* 2013, 110, 6021–6026. [CrossRef] [PubMed]

45. Koelsche, C.; Sahm, F.; Capper, D.; Reuss, D.; Sturm, D.; Jones, D.T.; Kool, M.; Northcott, P.A.; Wiestler, B.; Bohmer, K.; et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. *Acta Neuropathol.* 2012, 126, 907–915. [CrossRef] [PubMed]

46. Parsons, D.W.; Jones, S.; Zhang, X.; Lin, J.C.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I.M.; Gallia, G.L.; et al. An integrated genomic analysis of human glioblastoma multiforme. *Science* 2008, 321, 1807–1812. [CrossRef] [PubMed]

47. Yan, H.; Parsons, D.W.; Jin, G.; McLendon, R.; Rasheed, B.A.; Yuan, W.; Kos, I.; Batinic-Haberle, I.; Jones, S.; Riggins, G.J.; et al. IDH1 and IDH2 mutations in gliomas. *N. Engl. J. Med.* 2009, 360, 765–773. [CrossRef] [PubMed]

48. Xu, X.; Zhao, J.; Xu, Z.; Peng, B.; Huang, Q.; Arnold, E.; Ding, J. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. *J. Biol. Chem.* 2004, 279, 33946–33957. [CrossRef] [PubMed]

49. Joseph, J.W.; Jensen, M.V.; Ilkayeva, O.; Palmieri, F.; Alarcon, C.; Rhodes, C.J.; Newgard, C.B. The mitochondrial citrate/isocitrate carrier plays a regulatory role in glucose-stimulated insulin secretion. *J. Biol. Chem.* 2006, 281, 35624–35632. [CrossRef] [PubMed]

50. Lee, S.H.; Jo, S.H.; Lee, S.M.; Koh, H.J.; Song, H.; Park, J.W.; Lee, W.H.; Hub, T.L. Role of NADP+-dependent isocitrate dehydrogenase (NADP+-ICDH) on cellular defence against oxidative injury by gamma-rays. *Int. J. Radiat. Biol.* 2004, 80, 635–642. [CrossRef] [PubMed]

51. Ward, P.S.; Patel, J.; Wise, D.R.; Abdel-Wahab, O.; Bennett, B.D.; Collier, H.A.; Cross, J.R.; Fantin, V.R.; Hedvat, C.V.; Perl, A.E.; et al. Common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. *Cancer Cell* 2010, 17, 225–234. [CrossRef] [PubMed]

52. Figueroa, M.E.; Abdel-Wahab, O.; Lu, C.; Ward, P.S.; Patel, J.; Shih, A.; Li, Y.; Bhagwat, N.; Vasanthakumar, A.; Fernandez, H.F.; et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer Cell* 2010, 18, 553–567. [CrossRef]

53. Dang, L.; White, D.W.; Gross, S.; Bennett, B.D.; Bittinger, M.A.; Driggers, E.M.; Fantin, V.R.; Jang, H.G.; Jin, S.; Keenan, M.C.; et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature* 2009, 462, 739–744. [CrossRef]

54. Sturm, D.; Witt, H.; Hovestadt, V.; Khuong-Quang, D.A.; Jones, D.T.; Konermann, C.; Pfaff, E.; Tonjes, M.; Sill, M.; Bender, S.; et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. *Cancer Cell* 2012, 22, 425–437. [CrossRef] [PubMed]

55. Cairncross, J.G.; Ueki, K.; Zlatescu, M.C.; Lisle, D.K.; Finkelstein, D.M.; Hammond, R.R.; Silver, J.S.; Stark, P.C.; Macdonald, D.R.; Ino, Y.; et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. *J. Natl. Cancer Inst.* 1998, 90, 1473–1479. [CrossRef]

56. Kraus, J.A.; Koopmann, J.; Kaskel, P.; Maintz, D.; Brandner, S.; Schramm, J.; Louis, D.N.; Wiestler, O.D.; von Deimling, A. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglial and oligoastrocytoma. *J. Neuropathol. Exp. Neurol.* 1995, 54, 91–95. [CrossRef] [PubMed]

57. Polivka, J., Jr.; Polivka, J.; Repik, T.; Rohan, V.; Hes, O.; Topolcan, O. Co-deletion of 1p/19q as a Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma. *Anticancer Res.* 2016, 36, 471–476. [PubMed]

58. Reifenberger, J.; Reifenberger, G.; Liu, L.; James, C.D.; Wechsler, W.; Collins, V.P. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. *Am. J. Pathol.* 1994, 145, 1175–1190. [PubMed]

59. Bettegowda, C.; Agrawal, N.; Jiao, Y.; Sausen, M.; Wood, L.D.; Hruban, R.H.; Rodriguez, F.J.; Cahill, D.P.; McLeod, R.; Riggins, G.; et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. *Science* 2011, 333, 1453–1455. [CrossRef] [PubMed]

60. Jiao, Y.; Killela, P.J.; Reitman, Z.J.; Rasheed, A.B.; Heaphy, C.M.; de Wilde, R.F.; Rodriguez, F.J.; Rosenberg, S.; Obasaju, S.; Nagahashi Marie, S.K.; et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. *Oncotarget* 2012, 3, 709–722. [CrossRef]
61. Labussiere, M.; Idbaih, A.; Wang, X.W.; Marie, Y.; Boisselier, B.; Falet, C.; Paris, S.; Laffaire, J.; Carpentier, C.; Criniere, E.; et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. *Neurology* 2010, 74, 1886–1890. [CrossRef]

62. Duan, J.; Bao, X.; Ma, X.; Zhang, Y.; Ni, D.; Wang, H.; Zhang, F.; Du, Q.; Fan, Y.; Chen, J.; et al. Upregulation of Far Upstream Element-Binding Protein 1 (FUBP1) Promotes Tumor Proliferation and Tumorigenesis of Clear Cell Renal Cell Carcinoma. *PLoS ONE* 2017, 12, e0169852. [CrossRef]

63. Han, F.; Zhang, J.; Ma, S.; Chen, X.; Liu, W.; He, X.; Fei, Z.; Wang, Y. Altered capicua transcriptional repressor gene expression exhibits distinct prognostic value for isocitrate dehydrogenase-mutant oligodendrogliial tumors. *Oncol. Lett.* 2018, 15, 1459–1468. [CrossRef]

64. Cairncross, G.; Wang, M.; Shaw, E.; Jenkins, R.; Brachman, D.; Buckner, J.; Fink, K.; Souhami, L.; Laperriere, N.; Curran, W.; et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: Long-term results of RTOG 9402. *J. Clin. Oncol.* 2013, 31, 337–343. [CrossRef] [PubMed]

65. van den Bent, M.J.; Carpentier, A.F.; Brandes, A.A.; Sanson, M.; Taphoorn, M.J.; Bernsen, H.J.; Frenay, M.; Tijssen, C.C.; Grisold, W.; Sipos, L.; et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer phase III trial. *J. Clin. Oncol.* 2006, 24, 2715–2722. [PubMed]

66. Kaneshiro, D.; Kobayashi, T.; Chao, S.T.; Suh, J.; Prayson, R.A. Chromosome 1p and 19q deletions in *Cancer Genet.* 2013, 227, 41–48. [CrossRef] [PubMed]

67. Nakamura, M.; Yang, F.; Fujisawa, H.; Yonekawa, Y.; Kleihues, P.; Ohgaki, H. Loss of heterozygosity on chromosome 19 in secondary glioblastomas. *J. Neuropathol. Exp. Neurol.* 2000, 59, 539–543. [CrossRef] [PubMed]

68. Ohgaki, H.; Kleihues, P. Genetic pathways to primary and secondary glioblastoma. *Am. J. Pathol.* 2007, 170, 1445–1453. [CrossRef] [PubMed]

69. Filipescu, D.; Muller, S.; Almouzni, G. Histone H3 variants and their chaperones during development and disease: Contributing to epigenetic control. *Annu. Rev. Cell Dev. Biol.* 2014, 30, 615–646. [CrossRef] [PubMed]

70. Saleem, M.; Abbas, K.; Manan, M.; Ijaz, H.; Ahmed, B.; Ali, M.; Hanif, M.; Farooqi, A.A.; Qadir, M.I. Review-Epigenetic therapy for cancer. *Pak. J. Pharm. Sci.* 2015, 28, 1023–1032. [CrossRef] [PubMed]

71. Szenker, E.; Ray-Gallet, D.; Almouzni, G. The double face of the histone variant H3.3. *Cell Res.* 2011, 21, 421–434. [CrossRef] [PubMed]

72. Bannister, A.J.; Kouzarides, T. Regulation of chromatin by histone modifications. *Cell Res.* 2011, 21, 381–395. [CrossRef] [PubMed]

73. Wu, G.; Broniscer, A.; McEachron, T.A.; Lu, C.; Paugh, B.S.; Beckford, J.; Qu, C.; Ding, L.; Huether, R.; Parker, M.; et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. *Nat. Genet.* 2012, 44, 251–253. [CrossRef]

74. Bender, S.; Tang, Y.; Lindroth, A.M.; Hovestadt, V.; Jones, D.T.; Kool, M.; Zapatka, M.; Northcott, P.A.; Sturm, D.; Wang, W.; et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. *Cancer Cell* 2013, 24, 660–672. [CrossRef] [PubMed]

75. Buczkowicz, P.; Hoeman, C.; Rakopoulos, P.; Pajovic, S.; Letourneau, L.; Dzamba, M.; Morrison, A.; Lewis, P.; Bouffet, E.; Bartels, U.; et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. *Nat. Genet.* 2014, 46, 451–456. [CrossRef]

76. Fang, J.; Huang, Y.; Mao, G.; Yang, S.; Rennert, G.; Gu, L.; Li, H.; Li, G.M. Cancer-driving H3G34V/R/D mutations block H3K36 methylation and H3K36me3-MutSalpha interaction. *Proc. Natl. Acad. Sci. USA* 2018, 115, 9998–9603. [CrossRef] [PubMed]

77. Bjerke, L.; Mackay, A.; Nandhabalan, M.; Burford, A.; Jury, A.; Popov, S.; Bax, D.A.; Carvalho, D.; Taylor, K.R.; Vinci, M.; et al. Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. *Cancer Discov.* 2013, 3, 512–519. [CrossRef]

78. Martin, C.L.L. DH Telomeres. In *Handbook of Human Molecular Evolution*; John Wiley & Sons: Hoboken, NJ, USA, 2008; pp. 721–724.

79. Ruiz-Herrera, A.; Nergadze, S.G.; Santagostino, M.; Giulotto, E. Telomeric repeats far from the ends: Mechanisms of origin and role in evolution. *Cytogenet. Genome Res.* 2008, 122, 219–228. [CrossRef] [PubMed]

80. Liu, D.; O’Connor, M.S.; Qin, J.; Songyang, Z. Telosome, a mammalian telomere-associated complex formed by multiple telomeric proteins. *J. Biol. Chem.* 2004, 279, 51338–51342. [CrossRef]
81. Blasco, M.A. Telomere length, stem cells and aging. *Nat. Chem. Biol.* 2007, 3, 640–649. [CrossRef]
82. McClintock, B. The Stability of Broken Ends of Chromosomes in Zea Mays. *Genetics* 1941, 26, 234–282.
83. O’Sullivan, R.J.; Karleseder, J. Telomeres: Protecting chromosomes against genome instability. *Nat. Rev. Mol. Cell Biol.* 2010, 11, 171–181. [CrossRef]
84. Gong, J.G.; Costanzo, A.; Yang, H.Q.; Melino, G.; Kaelin, W.G., Jr.; Levrero, M.; Wang, J.Y. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. *Nature* 1999, 399, 806–809. [CrossRef]
85. Stiewe, T.; Putzer, B.M. p73 in apoptosis. *Apoptosis* 2001, 6, 447–452. [CrossRef] [PubMed]
86. VAZIRI, H.; DRAGOWSKA, W.; ALLSOPP, R.C.; THOMAS, T.E.; HARLEY, C.B.; LANSDORP, P.M. Evidence for a mitotic clock in human hematopoietic stem cells: Loss of telomeric DNA with age. *Proc. Natl. Acad. Sci. USA* 1994, 91, 9857–9860. [CrossRef] [PubMed]
87. Brouilette, S.; Singh, R.K.; Thompson, J.R.; Goodall, A.H.; Samani, N.J. White cell telomere length and risk of premature myocardial infarction. *Arterioscler. Thromb. Vasc. Biol.* 2003, 23, 842–846. [CrossRef] [PubMed]
88. Valdés, A.M.; Andrew, T.; Gardner, J.P.; Kimura, M.; Oelsner, E.; Cherkas, L.F.; Aviv, A.; Spector, T.D. Obesity, physical activity in leisure time and leukocyte telomere length: Evidence from the Cardiovascular Health Study. *Obesity* 2007, 15, 1459–1464. [CrossRef] [PubMed]
89. Frenck, R.W., Jr.; Blackburn, E.H.; Shannon, K.M. The rate of telomere sequence loss in human leukocytes varies with age. *Proc. Natl. Acad. Sci. USA* 1998, 95, 5607–5610. [CrossRef] [PubMed]
90. Dalgard, C.; Benetos, A.; Verhulst, S.; Labat, C.; Kark, J.D.; Christensen, K.; Kimura, M.; Kyvik, K.O.; Aviv, A. Leukocyte telomere length dynamics in women and men: Menopause vs age effects. *Int. J. Epidemiol.* 2015, 44, 1688–1695. [CrossRef] [PubMed]
91. Benetti, R.; Garcia-Cao, M.; Blasco, M.A. Telomere length regulates the epigenetic status of mammalian telomeres and subtelomeres. *Nat. Genet.* 2007, 39, 243–250. [CrossRef] [PubMed]
92. Celli, G.B.; de Lange, T. DNA processing is not required for ATM-mediated telomere damage response after TRF2 deletion. *Nat. Cell Biol.* 2005, 7, 712–718. [CrossRef]
93. Steinert, S.; Shay, J.W.; Wright, W.E. Modification of subtelomeric DNA. *Mol. Cell. Biol.* 2004, 24, 4571–4580. [CrossRef]
94. Adams, J.; Martin-Ruiz, C.; Pearce, M.S.; White, M.; Parker, L.; von Zglinicki, T. No association between socio-economic status and white blood cell telomere length. *Aging Cell* 2007, 6, 125–128. [CrossRef]
95. Cherkes, L.F.; Hunkin, J.L.; Kato, B.S.; Cherkas, L.F.; Aviv, A.; Spector, T.D. Telomere length regulates the epigenetic status of mammalian telomeres and subtelomeres. *Nat. Genet.* 2007, 39, 243–250. [CrossRef] [PubMed]
96. Telomere length in leukocytes correlates with bone mineral density and is shorter in women with osteoporosis. *Osteoporos. Int.* 2007, 18, 1203–1210. [CrossRef] [PubMed]
97. van der Harst, P.; van der Steege, G.; de Boer, R.A.; Voors, A.A.; Hall, A.S.; Mulder, M.J.; van Gilst, W.H.; van Veldhuisen, D.J.; MERIT-HF Study Group. Telomere length of circulating leukocytes is decreased in patients with chronic heart failure. *J. Am. Coll. Cardiol.* 2007, 49, 1459–1464. [CrossRef] [PubMed]
98. van der Harst, P.; van der Steege, G.; de Boer, R.A.; Voors, A.A.; Hall, A.S.; Mulder, M.J.; van Gilst, W.H.; van Veldhuisen, D.J.; MERIT-HF Study Group. Telomere length of circulating leukocytes is decreased in patients with chronic heart failure. *J. Am. Coll. Cardiol.* 2007, 49, 1459–1464. [CrossRef] [PubMed]
99. Zee, R.Y.; Michaud, S.E.; Germer, S.; Ridker, P.M. Association of shorter mean telomere length with risk of incident myocardial infarction: A prospective, nested case-control approach. *Clin. Chim. Acta* 2009, 403, 139–141. [CrossRef] [PubMed]
100. Sampson, M.J.; Winterbone, M.S.; Hughes, J.C.; Dozio, N.; Hughes, D.A. Monocyte telomere shortening and oxidative DNA damage in type 2 diabetes. *Diabetes Care* 2006, 29, 283–289. [CrossRef] [PubMed]
101. Valdés, A.M.; Richards, J.B.; Gardner, J.P.; Swaminathan, R.; Kimura, M.; Xiaobin, L.; Aviv, A.; Spector, T.D. Telomere length in leukocytes correlates with bone mineral density and is shorter in women with osteoporosis. *Osteoporos. Int.* 2007, 18, 1203–1210. [CrossRef] [PubMed]
102. Cawthon, R.M.; Smith, K.R.; O’Brien, E.; Sivatchenko, A.; Kerber, R.A. Association between telomere length in blood and mortality in people aged 60 years or older. *Lancet* 2003, 361, 393–395. [CrossRef]
104. Farzaneh-Far, R.; Cawthon, R.M.; Na, B.; Browner, W.S.; Schiller, N.B.; Whooley, M.A. Prognostic value of leukocyte telomere length in patients with stable coronary artery disease: Data from the Heart and Soul Study. *Arterioscler. Thromb. Vasc. Biol.* **2008**, *28*, 1379–1384. [CrossRef] [PubMed]

105. Yang, Z.; Huang, X.; Jiang, H.; Zhang, Y.; Liu, H.; Qin, C.; Eisner, G.M.; Jose, P.A.; Rudolph, L.; Ju, Z. Short telomeres and prognosis of hypertension in a chinese population. *Hypertension* **2009**, *53*, 639–645. [CrossRef]

106. Chin, L.; Artandi, S.E.; Shen, Q.; Tam, A.; Lee, S.L.; Gottlieb, G.J.; Greider, C.W.; DePinho, R.A. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. *Cell* **1999**, *97*, 527–538. [CrossRef]

107. De Lange, T. Telomere-related genome instability in cancer. *Cold Spring Harb. Symp. Quant. Biol.* **2005**, *70*, 197–204. [CrossRef] [PubMed]

108. Meeker, A.K. Telomeres and telomerase in prostatic intraepithelial neoplasia and prostate cancer biology. *Urol. Oncol.* **2006**, *24*, 122–130. [CrossRef] [PubMed]

109. Shay, J.W.; Wright, W.E. Role of telomeres and telomerase in cancer. *Semin. Cancer Biol.* **2011**, *21*, 349–353. [CrossRef]

110. Wu, K.; Higashi, N.; Hansen, E.R.; Lund, M.; Bang, K.; Thstrup-Pedersen, K. Telomerase activity is increased and telomere length shortened in T cells from blood of patients with atopic dermatitis and psoriasis. *J. Immunol.* **2000**, *165*, 4742–4747. [CrossRef]

111. Greider, C.W.; Blackburn, E.H. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. *Cell* **1985**, *43*, 405–413. [CrossRef]

112. Moyzis, R.K.; Buckingham, J.M.; Cram, L.S.; Dani, M.; Deaven, L.L.; Jones, M.D.; Meyne, J.; Ratliff, R.L.; Wu, J.R. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. *Proc. Natl. Acad. Sci. USA* **1988**, *85*, 6622–6626. [CrossRef] [PubMed]

113. Shippen-Lentz, D.; Blackburn, E.H. Functional evidence for an RNA template in telomerase. *Science* **1990**, *247*, 546–552. [CrossRef]

114. Hiyama, K.; Hirai, Y.; Kyoizumi, S.; Akiyama, M.; Hiyama, E.; Piatyszek, M.A.; Shay, J.W.; Ishioka, S.; Yamakido, M. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. *J. Immunol.* **1995**, *155*, 3711–3715.

115. Kim, N.W.; Piatyszek, M.A.; Prowse, K.R.; Harley, C.B.; West, M.D.; Ho, P.L.; Covello, G.M.; Wright, W.E.; Weinrich, S.L.; Shay, J.W. Specific association of human telomerase activity with immortal cells and cancer. *Science* **1994**, *266*, 2011–2015. [CrossRef] [PubMed]

116. Meyne, J.; Ratliff, R.L.; Moyzis, R.K. Conservation of the human telomere sequence (TTAGGG)n among vertebrates. *Proc. Natl. Acad. Sci. USA* **1989**, *86*, 7049–7053. [CrossRef] [PubMed]

117. Feng, J.; Funk, W.D.; Wang, S.S.; Weinrich, S.L.; Avilion, A.A.; Chiu, C.P.; Allsopp, R.C.; Yu, J.; et al. The RNA component of human telomerase. *Science* **1995**, *269*, 1236–1241. [CrossRef] [PubMed]

118. Mocellin, S.; Pooley, K.A.; Nitti, D. Telomerase and the search for the end of cancer. *Trends Mol. Med.* **2013**, *19*, 125–133. [CrossRef]

119. Smekalova, E.M.; Shubernetskaya, O.S.; Zvereva, M.I.; Gromenko, E.V.; Rubtsova, M.P.; Dontsova, O.A. Telomerase RNA biosynthesis and processing. *Biochemistry* **2012**, *77*, 1120–1128. [CrossRef]

120. Horn, S.; Figl, A.; Rachakonda, P.S.; Fischer, C.; Sucker, A.; Gast, A.; Kadel, S.; Moll, I.; Nagore, E.; Hemminki, K.; et al. TERT promoter mutations in familial and sporadic melanoma. *Science* **2013**, *339*, 959–961. [CrossRef]

121. Huang, F.W.; Hodis, E.; Xu, M.J.; Kryukov, G.V.; Chin, L.; Garraway, L.A. Highly recurrent TERT promoter mutations in human melanoma. *Science* **2013**, *339*, 957–959. [CrossRef]

122. Liu, X.; Wu, G.; Shan, Y.; Hartmann, C.; von Deimling, A.; Xing, M. Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. *Cell Cycle* **2013**, *12*, 1637–1638. [CrossRef]

123. Arita, H.; Narita, Y.; Takami, H.; Fukushima, S.; Matsushita, Y.; Yoshida, A.; Miyakita, Y.; Ohno, M.; Shibui, S.; Ichimura, K. TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas. *Acta Neuropathol.* **2013**, *126*, 939–941. [CrossRef]

124. Brennan, C.W.; Verhaak, R.G.; McKenna, A.; Campos, B.; Noushmehr, H.; Salama, S.R.; Zheng, S.; Chakravarty, D.; Sanborn, J.Z.; Berman, S.H.; et al. The somatic genomic landscape of glioblastoma. *Cell* **2013**, *155*, 462–477. [CrossRef]
125. Nonoguchi, N.; Ohta, T.; Oh, J.E.; Kim, Y.H.; Kleihues, P.; Ohgaki, H. TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol. 2013, 126, 931–937. [CrossRef] [PubMed]
126. Vinagre, J.; Almeida, A.; Populo, H.; Batista, R.; Lyra, J.; Pinto, V.; Coelho, R.; Celestino, R.; Prazeres, H.; Lima, L.; et al. Frequency of TERT promoter mutations in human cancers. Nat. Commun. 2013, 4, 2185. [CrossRef] [PubMed]
127. Heaphy, C.M.; de Wilde, R.F.; Jiao, Y.; Klein, A.P.; Edil, B.H.; Shi, C.; Bettegowda, C.; Rodriguez, F.J.; Eberhart, C.G.; Hebbar, S.; et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011, 333, 425. [CrossRef] [PubMed]
128. Schwartzztruber, J.; Korshunov, A.; Liu, X.Y.; Jones, D.T.; Pfaff, E.; Jacob, K.; Sturm, D.; Fontebasso, A.M.; Quang, D.A.; Tonjes, M.; et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012, 482, 226–231. [CrossRef] [PubMed]
129. Molano, M.; Martin, D.C.; Moreno-Acosta, P.; Hernandez, G.; Cornall, A.; Buitrago, O.; Gamboa, O.; Garland, S.; Tabrizi, S.; Munoz, N. Telomerase activity in cervical scrapes of women with high-grade cervical disease: A nested case-control study. Oncol. Lett. 2018, 15, 354–360. [CrossRef]
130. Wang, N.; Xu, D.; Sofiadis, A.; Hoog, A.; Vukojevic, V.; Backdahl, M.; Zedenius, J.; Larsson, C. Telomerase-dependent and independent telomere maintenance and its clinical implications in medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 2014, 99, E1571–E1579. [CrossRef] [PubMed]
131. Bornstein-Quevedo, L.; Garcia-Hernandez, M.L.; Camacho-Arroyo, I.; Herrera, M.F.; Angeles, A.A.; Trevino, O.G.; Gamboa-Dominguez, A. Telomerase activity in well-differentiated papillary thyroid carcinoma correlates with advanced clinical stage of the disease. Endocr. Pathol. 2003, 14, 213–219. [CrossRef]
132. Fernandez-Marcelo, T.; Gomez, A.; Pascua, I.; de Juan, C.; Head, J.; Hernando, F.; Jarabo, J.R.; Calatayud, J.; Torres-Garcia, A.J.; Iniesta, P. Telomere length and telomerase activity in non-small cell lung cancer prognosis: Clinical usefulness of a specific telomere status. J. Exp. Clin. Cancer Res. 2015, 34, 78. [CrossRef]
133. Satyanarayana, A.; Manns, M.P.; Rudolph, K.L. Telomeres and telomerase: A dual role in hepatocarcinogenesis. Hepatology 2004, 40, 276–283. [CrossRef]
134. Bryan, T.M.; Englezou, A.; Dalla-Pozza, L.; Dunham, M.A.; Reddel, R.R. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat. Med. 1997, 3, 1271–1274. [CrossRef]
135. Slatter, T.L.; Tan, X.; Yuen, Y.C.; Gunningham, S.; Ma, S.S.; Daly, E.; Packer, S.; Devenish, C.; Royds, J.A.; Hung, N.A. The alternative lengthening of telomeres pathway may operate in non-neoplastic human cells. J. Pathol. 2012, 226, 509–518. [CrossRef] [PubMed]
136. Heaphy, C.M.; Subhawong, A.P.; Hong, S.M.; Goggins, M.G.; Montgomery, E.A.; Gabrielson, E.; Netto, G.J.; Epstein, J.J.; Lotan, T.L.; Westra, W.H.; et al. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am. J. Pathol. 2011, 179, 1608–1615. [CrossRef] [PubMed]
137. Westler, B.; Capper, D.; Holland-Letz, T.; Korshunov, A.; von Deimling, A.; Pfister, S.M.; Platten, M.; Weller, M.; Wick, W. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol. 2013, 126, 443–451. [CrossRef] [PubMed]
138. Flynn, R.L.; Cox, K.E.; Jeitany, M.; Wakimoto, H.; Bryll, A.R.; Ganem, N.J.; Bersani, F.; Pineda, J.R.; Suva, M.L.; Benes, C.H.; et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science 2015, 347, 273–277. [CrossRef] [PubMed]
139. Shay, J.W.; Reddel, R.R.; Wright, W.E. Cancer and telomeres—An ALTernative to telomerase. Science 2012, 336, 1388–1390. [CrossRef] [PubMed]
140. Cesare, A.J.; Reddel, R.R. Alternative lengthening of telomeres: Models, mechanisms and implications. Nat. Rev. Genet. 2010, 11, 319–330. [CrossRef] [PubMed]
141. Gibbons, R. Alpha thalassaemia-mental retardation, X linked. Orphanet J. Rare Dis. 2006, 1, 15. [CrossRef] [PubMed]
142. Dyer, M.A.; Qadeer, Z.A.; Valle-Garcia, D.; Bernstein, E. ATRX and DAXX: Mechanisms and Mutations. Cold Spring Harb. Perspect. Med. 2017, 7, a025657. [CrossRef]
143. Pekmezci, M.; Rice, T.; Molinaro, A.M.; Walsh, K.M.; Decker, P.A.; Hansen, H.; Sicotte, H.; Kollmeyer, T.M.; McCoy, L.S.; Sarkar, G.; et al. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: Additional prognostic roles of ATRX and TERT. Acta Neuropathol. 2017, 133, 1001–1016. [CrossRef]
144. Clynes, D.; Higgs, D.R.; Gibbons, R.J. The chromatin remodeler ATRX: A repeat offender in human disease. *Trends Biochem. Sci.* 2013, 38, 461–466. [CrossRef]

145. Napier, C.E.; Huschtscha, L.I.; Harvey, A.; Bower, K.; Noble, J.R.; Hendrickson, E.A.; Reddel, R.R. ATRX represses alternative lengthening of telomeres. *Oncotarget* 2015, 6, 16543–16558. [CrossRef] [PubMed]

146. Clynes, D.; Jelinska, C.; Xella, B.; Ayyub, H.; Taylor, S.; Mitson, M.; Bachrati, C.Z.; Higgs, D.R.; Gibbons, R.J. ATRX dysfunction induces replication defects in primary mouse cells. *PLoS ONE* 2014, 9, e92915. [CrossRef] [PubMed]

147. Eid, R.; Demattei, M.V.; Episkopou, H.; Auge-Gouillou, C.; Decottignies, A.; Grandin, N.; Charbonneau, M. Genetic Inactivation of ATRX Leads to a Decrease in the Amount of Telomeric Cohesin and Level of Telomere Transcription in Human Glioma Cells. *Mol. Cell. Biol.* 2015, 35, 2818–2830. [CrossRef] [PubMed]

148. Yang, X.; Khosravi-Far, R.; Chang, H.Y.; Baltimore, D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. *Cell* 1997, 89, 1067–1076. [CrossRef]

149. Drane, P.; Ouararhni, K.; Depaux, A.; Shuaib, M.; Hamiche, A. The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. *Genes Dev.* 2010, 24, 1253–1265. [CrossRef] [PubMed]

150. Goldber, A.D.; Banaszynski, L.A.; Noh, K.M.; Lewis, P.W.; Elsasser, S.J.; Stadler, S.; Dewell, S.; Law, M.; Guo, X.; Li, X.; et al. Distinct factors control histone variant H3.3 localization at specific genomic regions. *Cell* 2010, 140, 678–691. [CrossRef]

151. Hu, Y.; Shi, G.; Zhang, L.; Li, F.; Jiang, Y.; Jiang, S.; Ma, W.; Zhao, Y.; Songyang, Z.; Huang, J. Switch telomerase to ALT mechanism by inducing telomeric DNA damages and dysfunction of ATRX and DAXX. *Sci. Rep.* 2016, 6, 32280. [CrossRef] [PubMed]

152. Roth, A.; Harley, C.B.; Baerlocher, G.M. Imetelstat (GRN163L)—Telomerase-based cancer therapy. *Recent Results Cancer Res.* 2010, 184, 221–234. [PubMed]

153. Ouellette, M.M.; Wright, W.E.; Shay, J.W. Targeting telomerase-expressing cancer cells. *J. Cell. Mol. Med.* 2011, 15, 1433–1442. [CrossRef]
182. Tsai, N.M.; Lin, S.Z.; Lee, C.C.; Chen, S.P.; Su, H.C.; Chang, W.L.; Harn, H.J. The antitumor effects of Angelica sinensis on malignant brain tumors in vitro and in vivo. *Clin. Cancer Res.* **2005**, *11*, 3475–3484. [CrossRef] [PubMed]

183. Yu, Y.L.; Su, K.J.; Chen, C.J.; Wei, C.W.; Lin, C.J.; Yang, G.T.; Lin, S.Z.; Harn, H.J.; Chen, Y.L. Synergistic anti-tumor activity of isoachaialactone and paclitaxel on human lung cancer cells. *J. Cell. Physiol.* **2012**, *227*, 213–222. [CrossRef] [PubMed]

184. Lin, P.C.; Lin, S.Z.; Chen, Y.L.; Chang, J.S.; Ho, L.I.; Liu, P.Y.; Chang, L.F.; Harn, Y.C.; Chen, S.P.; Sun, L.Y.; et al. Butylidenephthalide suppresses human telomerase reverse transcriptase (TERT) in human glioblastomas. *Ann. Surg. Oncol.* **2011**, *18*, 3514–3527. [CrossRef] [PubMed]

185. Tsai, N.M.; Chen, Y.L.; Lee, C.C.; Lin, P.C.; Cheng, Y.L.; Chang, W.L.; Lin, S.Z.; Harn, H.J. The natural compound n-butylidenephthalide derived from Angelica sinensis inhibits malignant brain tumor growth in vitro and in vivo. *J. Neurochem.* **2006**, *99*, 1251–1262. [CrossRef]

186. Yen, S.Y.; Chen, S.R.; Hsieh, J.; Li, Y.S.; Chuang, S.E.; Chuang, H.M.; Huang, M.H.; Lin, S.Z.; Harn, H.J.; Chiou, T.W. Biodegradable interstitial release polymer loading a novel small molecule targeting Axl receptor tyrosine kinase and reducing brain tumour migration and invasion. *Oncogene* **2016**, *35*, 2156–2165. [CrossRef]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).